CareDx Partners with Dovetail Genomics for Advanced Transplant Solutions
CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, has formed a strategic partnership with Dovetail Genomics, a leader in genomic solutions. Together, these companies are on a mission to revolutionize HLA genotyping, an essential aspect of organ and stem cell transplant matching.
Innovative HLA Typing Solutions
In this partnership, HLA laboratories will gain access to an Early Access Program. This initiative utilizes CareDx’s NGS-based AlloSeq™ Tx 17 HLA typing solution, which integrates Dovetail Genomics’ groundbreaking Hi-C technology. By merging these technologies, HLA labs can perform high-resolution genotyping and haplotyping without the traditional need for family genotyping studies. This advancement holds substantial promise for enhancing the prospects of long-term successful donor-recipient matches.
CareDx’s Commitment to Innovation
John W. Hanna, the President and CEO of CareDx, emphasized the importance of innovation in this collaboration, stating, "This collaboration reflects CareDx’s commitment to innovation in the transplant field, highlighted by our industry-first with AlloSeq Tx 17, the first HLA typing solution to cover 17 loci. This partnership positions HLA labs to leverage cutting-edge solutions, enabling them to evaluate innovative donor-recipient matching methods."
HLA Typing and Genomic Research
One of the standout features of CareDx’s AlloSeq Tx 17 is its efficient, market-leading NGS-based HLA typing solution. Its innovative hybrid-capture workflow simplifies donor matching studies while expanding the gene content beyond the classical 11 HLA loci, providing a more comprehensive picture. In concert with Dovetail Genomics’ LinkPrep technology, this solution introduces a pioneering method for producing complete HLA haplotypes.
LinkPrep Technology’s Impact
LinkPrep technology stands out in the field of genomic solutions. It allows for direct phasing information from linked long-range reads, simplifying tasks like long-distance inter-locus phasing and haplotype determination. The coupling of AlloSeq Tx with LinkPrep therefore offers a tremendous opportunity for researchers to assess the benefits of precise and complete HLA haplotypes in donor-recipient matching processes.
Transforming the Transplant Community
Matt Easterday, Ph.D., J.D., CEO of Dovetail Genomics, remarked on the implications for the transplant community. He noted, "Dovetail Genomic’s LinkPrep technology’s unique ability to capture haplotype-aware genetic variation will be a game-changer for applications like HLA testing. The transplant community now has a vital tool that will aid in optimizing transplant matching, thereby improving patient outcomes."
Clinical Study Showcase
The combined performance of AlloSeq Tx and LinkPrep technology will be showcased through clinical study samples at an upcoming symposium hosted by CareDx at the annual American Society for Histocompatibility and Immunogenetics (ASHI) meeting. This symposium, titled “Future of Transplant Solutions: Innovation Across the Pre-and Post-Transplant Journey,” will be held on October 23, 2024. HLA labs interested in this early access program are encouraged to connect with their CareDx representative for further information.
About CareDx and Dovetail Genomics
About CareDx: Headquartered in Brisbane, California, CareDx is dedicated to providing precision medicine solutions for transplant patients and caregivers. The company specializes in offering testing services and digital healthcare solutions that enhance patient care throughout the pre- and post-transplant journey. As a leader in genomics-based information for transplant patients, CareDx continues to push the boundaries of innovation.
About Dovetail Genomics: Dovetail Genomics operates as a subsidiary of Cantata Bio and is at the forefront of genomics solutions. The company leverages proprietary proximity ligation technologies to study the complex architecture of the genome. Their methods are instrumental in various research fields, including chromatin topology, structural variant detection, and microbiome analysis.
Frequently Asked Questions
What is the primary focus of the partnership between CareDx and Dovetail Genomics?
The partnership primarily focuses on advancing HLA genotyping technology to improve organ and stem cell transplant matching processes.
What technology is CareDx utilizing in this partnership?
CareDx is employing its NGS-based AlloSeq™ Tx 17 HLA typing solution along with Dovetail’s Hi-C technology to enhance the precision of HLA typing.
What are the benefits of high-resolution genotyping?
High-resolution genotyping allows for better donor-recipient matching, leading to improved long-term success rates in transplants.
How can HLA labs participate in the Early Access Program?
HLA labs interested in participating in the Early Access Program should reach out to their CareDx representative for more information.
When will the combined AlloSeq Tx and LinkPrep technology be showcased?
The technology will be presented at the upcoming ASHI meeting on October 23, 2024, during a CareDx symposium and poster session.
